Health Trials

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

ConditionUlcerative Colitis (UC)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXencor, Inc.

About this trial

Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Eligibility criteria

Qualifiers

Age 18-55

Must be in good health with no significant medical history

Clinical laboratory values within normal range

BMI 18-35 (inclusive)

Disqualifiers

Any physical or psychological condition that prohibits study completion

History of suicidal behavior or suicidal ideation

Heavy use of nicotine containing products

HIV, hepatitis B and hepatitis C positive

Trial design

Treatments tested in this trial

  • XmAb942
  • Placebo

Treatment groups

270 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Locations

66
Australia
Xencor Investigative Site2500, WollongongNew South Wales, Australia
Xencor Investigative Site4101, South BrisbaneQueensland, Australia
Xencor Investigative Site4215, SouthportQueensland, Australia
Xencor Investigative Site6027, JoondalupWestern Australia, Australia

Sponsors and collaborators

Xencor, Inc.

Lead sponsor

Source ClinicalTrials.gov